高危前列腺癌前列腺及盆腔淋巴结中度大分割调强质子治疗晚期毒性
一项前瞻性研究纳入56例高危或不良中危前列腺癌患者,采用中度大分割调强质子治疗(IMPT)同步照射前列腺6750 cGy(RBE)和盆腔淋巴结4500 cGy(RBE),分25次,全部接受雄激素剥夺治疗。54例可评估晚期毒性,中位随访43.9个月,晚期≥2级胃肠道毒性2年和3年均为7.4%,晚期≥2级泌尿生殖毒性2年20.5%、3年29.2%,无3级泌尿生殖毒性。结论认为该方案总体耐受良好,基线泌尿生殖症状与晚期2级泌尿生殖毒性较高相关,需3期研究评估疗效增益。
要点
- 晚期≥2级胃肠道毒性2年和3年均为7.4%(95%CI 0.2%-14.2%),3级为1.9%(95%CI 0%-5.4%)。
- 晚期≥2级泌尿生殖毒性2年为20.5%(95%CI 8.9%-30.6%),3年为29.2%(95%CI 15.5%-40.7%),无3级。
- 基线存在泌尿生殖症状与晚期2级泌尿生殖毒性发生率较高相关。
核心结论
- 中度大分割IMPT靶向前列腺和区域盆腔淋巴结总体耐受良好。
- 基线存在泌尿生殖症状的患者晚期2级泌尿生殖毒性发生率较高。
- 需要3期研究评估IMPT与光子放疗相比的任何治疗增益。
研究设计与样本
- 前瞻性研究(ClinicalTrials.gov:NCT02874014),目标入组56例高危或不良中危前列腺癌患者。
- 采用笔束扫描IMPT,同步给予前列腺6750 cGy(RBE)和盆腔淋巴结4500 cGy(RBE),分25次每日照射。
- 全部患者接受雄激素剥夺治疗。
- 采用不良事件通用术语标准4.0版前瞻性评估晚期胃肠道和泌尿生殖毒性,时间点为基线、放疗期间每周、放疗后3个月,之后每6个月。
- 采用Kaplan-Meier法估计晚期胃肠道和泌尿生殖毒性的 actuarial 率。
主要发现
- 中位年龄75.5岁,54例可进行晚期毒性评估,中位随访43.9个月(范围16-66)。
- 晚期≥2级胃肠道毒性2年和3年 actuarial 率均为7.4%(95%CI 0.2%-14.2%)。
- 晚期3级胃肠道毒性2年和3年 actuarial 率均为1.9%(95%CI 0%-5.4%),1例患者发生3级胃肠道毒性(直肠炎)。
- 晚期≥2级泌尿生殖毒性 actuarial 率2年为20.5%(95%CI 8.9%-30.6%),3年为29.2%(95%CI 15.5%-40.7%)。
- 无患者发生3级泌尿生殖毒性。
关键数值与推荐
- 晚期≥2级胃肠道毒性2年和3年 actuarial 率均为7.4%(95%CI 0.2%-14.2%)。
- 晚期3级胃肠道毒性2年和3年 actuarial 率均为1.9%(95%CI 0%-5.4%)。
- 晚期≥2级泌尿生殖毒性 actuarial 率2年为20.5%(95%CI 8.9%-30.6%),3年为29.2%(95%CI 15.5%-40.7%)。
- 无3级泌尿生殖毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要3期研究评估IMPT与光子放疗相比的任何治疗增益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate late gastrointestinal (GI) and genitourinary (GU) toxicity of moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes. METHODS AND MATERIALS: A target accrual of 56 patients with high-risk or unfavorable intermediate risk prostate cancer were enrolled into a prospective study (ClinicalTrials.gov: NCT02874014) of moderately hypofractionated IMPT. IMPT with pencil beam scanning was used to deliver 6750 and 4500 cGy relative biological effectiveness in 25 daily fractions simultaneously to the prostate and pelvic lymph nodes, respectively. All received androgen deprivation therapy. Late GI and GU toxicity was prospectively assessed using Common Terminology Criteria for Adverse Events version 4.0, at baseline, weekly during radiation therapy, 3-month postradiation therapy, and then every 6 months. Actuarial rates of late GI and GU toxicity were estimated using Kaplan-Meier method. RESULTS: Median age was 75.5 years. Fifty-four patients were available for late toxicity evaluation. Median follow-up was 43.9 months (range, 16-66). The actuarial rate of late grade ≥2 GI toxicity at both 2 and 3 years was 7.4% (95% confidence interval [CI], 0.2%-14.2%). The actuarial rate of late grade 3 GI toxicity at both 2 and 3 years was 1.9% (95% CI, 0%-5.4%). One patient experienced grade 3 GI toxicity with proctitis. The actuarial rate of late grade ≥2 GU toxicity was 20.5% (95% CI, 8.9%-30.6%) at 2 years, and 29.2 % (95% CI, 15.5%-40.7%) at 3 years. None had grade 3 GU toxicity. The presence of baseline GU symptoms was associated with a higher likelihood of experiencing late grade 2 GU toxicity. CONCLUSIONS: A moderately hypofractionated IMPT targeting the prostate and regional pelvic lymph nodes was generally well tolerated. Patients with pre-existing GU symptoms had a higher rate of late grade 2 GU toxicity. A phase 3 study is needed to assess any therapeutic gain of IMPT, in comparison with photon-based radiation therapy.
引用
- Choo R, Hillman DW, Mitchell C, et al. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 36427645. doi:10.1016/j.ijrobp.2022.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。